Sector News

Lilly announces changes in senior management

March 2, 2017
Life sciences

Eli Lilly and Company today announced changes in its executive committee.

Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Development.
Bart Peterson, senior vice president of Corporate Affairs and Communications, will leave Lilly March 31 to pursue personal business interests and expand his community volunteer commitments. Peterson, a former two-term mayor of Indianapolis, joined Lilly in 2009. A search currently is under way for his replacement.

“Fionnuala and Bart have been invaluable members of our executive committee as our business has gone through tremendous transformation during the last few years,” said David Ricks, Lilly president and CEO. “Fionnuala has worked diligently to ensure that we have maintained the highest quality standards across our worldwide operations, which is absolutely essential to our business. And, Bart’s leadership and political acumen have been vital to help us meet the significant challenges of an incredibly complex health care environment. His strong passion and vision for global health has been instrumental in making life better for people around the world.”

Ricks said Lilly is very fortunate to have Norton to step into Walsh’s role. “Johna lives Lilly’s values every day, has a strong commitment to our mission, sets the highest standards for her work and has demonstrated leadership in partnering across the business. She has a deep knowledge of our manufacturing and quality systems and has worked effectively with regulators globally.”

Source: Eli Lilly and Company

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.